19 results
Thumbnail

D3.260 - Shiitake-Induced Flagellate Dermatitis: Case Series from Kazakhstan

Thumbnail

D3.261 - Orphan Diseases In Allergology - Melkersson-Rosenthal Syndrome

Thumbnail

D3.264 - Delayed Type Hypersensitivity Injection Site Reaction Induced By Liraglutide

Thumbnail

D3.265 - Gleish syndrome: A case report

Thumbnail

D3.266 - Component-Resolved Delayed Hypersensitivity to Piperacillin/Tazobactam and Clavulanic Acid Despite Structural Divergence

Thumbnail

D3.267 - Statistics of Contributing Factors to Atopic Dermatitis in Children

Thumbnail

D3.256 - A Child with Mastocytosis presenting with generalized severe Pruritus: A Diagnostic Pitfall

Thumbnail

D3.258 - Not just a rash: a delayed diagnosis of allopurinol-induced dress syndrome

Thumbnail

D1.437 - A Decade of Research on Janus Kinase Inhibitors in Atopic Dermatitis: A Global Bibliometric Analysis (2015–2024)

Thumbnail

D1.438 - Dupilumab for Moderate-to-Severe Atopic Dermatitis in Children and Adolescents: Real-Life Assessment of Efficacy and Safety

Thumbnail

D1.442 - Design and Preclinical Development of a Bispecific Antibody Targeting IL11 and TL1A

Thumbnail

D1.443 - Preclinical Development of a Dual LIGHT/TL1A Bispecific Antibody

Thumbnail

D1.446 - Lebrikizumab in patients with urticarial vasculitis - a case series

Thumbnail

D1.447 - Comparison of Disease Duration, Remission, and Other Disease-Related Parameters with the Duration of Omalizumab Treatment in Patients with Chronic Spontaneous Urticaria

Thumbnail

D1.448 - Long-Term Efficacy and Stability of Lebrikizumab in Treating Face/Head and Neck Involvement in Patients with Moderate-to-Severe Atopic Dermatitis

Thumbnail

D1.449 - A Phase 2, Open-Label Extension Study to Evaluate the Long-Term Safety and Efficacy of Briquilimab in Adults with Chronic Urticaria (Trial in Progress)

Thumbnail

D1.439 - Urticaria Voices: Physician-reported perspectives of chronic urticaria care and its treatment in China (UV in China)

Thumbnail

D1.441 - A Bispecific Antibody Targeting IL13 and IL31 for the Treatment of Inflammatory Skin Diseases

Thumbnail

D1.444 - Dual Blockade of IL22 and IL23 with a bispecific antibody: A Promising Strategy for the Treatment of Psoriasis and Other Autoimmune Skin Disorders